KONEXElectrical Equipment244880

Nanoomtech

₩1,598▼ 10.68%2026-11-18 close
Market Cap
₩8B
Turnover
₩3,404,222
Volume
2.2K
Shares out.
5M
PER
—
PBR
—
EPS
—
Dividend Yield
6.26%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

An AED maker with solid margins and thin liquidity

Nanoomtech posted an operating margin of roughly 20% on a 2025 standalone basis, but its KONEX listing, 8.4 billion won market cap and AED concentration remain the key variables.

  1. 1

    On a 2025 standalone basis, operating profit was 3,338 million won, an operating margin of about 20%.

  2. 2

    Revenue is concentrated in AED manufacturing, with bone densitometers and knee stimulators as secondary products.

  3. 3

    The fiscal 2025 year-end dividend is 100 won per common share, a 4.18% dividend yield at market price.

  4. 4

    According to an October 2026 filing, the largest shareholder's stake rose 0.14 percentage points to 46.19%.

  5. 5

    The company is listed on KONEX, with a market cap of 8.4 billion won and a share price of 1,676 won.

02

Business structure

Nanoomtech is a medical device manufacturer based in Gwangju that produces automated external defibrillators (AEDs) as its core product. The exchange classifies it under electrical equipment, but its business is in medical device manufacturing.

In 2019, the medical equipment manufacturing segment accounted for 91.5% of revenue, the product segment for storage units and similar items for 8.0%, and services and rental for 0.5%. Within medical equipment, AED manufacturing made up 99.6% of segment sales.

The lineup includes AED models such as ReHeart and HeartPlus, along with X-ray bone densitometers and a knee high-frequency stimulator. The NT-381.AI model adds an AI algorithm for ECG analysis.

Sales rely heavily on public procurement through the Public Procurement Service, supplemented by private demand from hospitals, clinics and public facilities. Over the three years through the 2019 business report, domestic sales accounted for more than 86% of revenue.

The company holds CE, Japanese PMDA, Australian TGA and Mexican FDA certifications, which form the basis for exports. A 2020 KONEX research report credited the company's intellectual property with supporting a price premium. The claim of being the domestic AED leader comes from the company's own product profile. Its high-frequency stimulator remains in performance-improvement research.

03

Recent trends

The March 31, 2026 shareholder meeting approved the fiscal 2025 financial statements (21st term).

On a standalone basis, 2025 revenue was 16,349 million won, operating profit 3,338 million won and net income 3,258 million won, with total assets of 28,935 million won, total liabilities of 2,300 million won and equity of 26,635 million won. The implied operating margin is around 20%, and leverage is low.

According to FnGuide, 2024 revenue was 16.1 billion won, operating profit 2.8 billion won and the operating margin 17.53%. ROE fell to 13.48% in 2024 from 19.18% in 2023. Revenue edged up to the mid-16 billion won range in 2025, while operating profit rose from 2.8 billion won to the mid-3 billion won range.

A February 13, 2026 filing set a year-end dividend of 100 won per common share, with a total payout of 502 million won and a 4.18% dividend yield at market price.

An October 2026 filing reported that the largest shareholder's stake rose 0.14 percentage points to 46.19%, and the change was recorded as on-market purchases. The current price is 1,676 won (-0.53% from the prior close), and the market cap is 8.4 billion won.

Based on external market data, the 52-week range is 1,500 to 2,450 won. Some financial data sites show different 2024 revenue figures, so the year-on-year comparison relies on the shareholder-approved statements.

04

Outlook

The main business variable is the mix between public procurement and private demand. In 2019, procurement orders from the Public Procurement Service carried a large share of sales, and in the first half of 2020 sales fell 25.7% year on year after government budgets were cut.

On exports, the CE, PMDA, TGA and Mexican certifications provide a route to widen overseas sales. On product diversification, the NT-381.AI model with AI ECG analysis and the high-frequency stimulator research are the main items.

Operating margin fell from 22.51% in 2023 to 17.53% in 2024 and is calculated at around 20% for 2025. With the largest shareholder holding 46.19%, the free float available for trading is limited. The annual cash dividend stayed at 100 won per share for both 2024 and 2025.

Items to track next are the revenue mix and operating margin in the 2026 quarterly reports, procurement award activity and whether the high-frequency stimulator contributes meaningful revenue.

05

Bull factors

AED demand from public and private buyers

AED sales draw on both public procurement and private facility demand. A KONEX report credited mandatory installation and growing private demand with sustained sales growth over three years. Domestic sales were above 86% in 2019, so the revenue base is concentrated at home but spread across buyer types.

Patent-backed pricing power

A KONEX report credited the company's intellectual property with a price advantage. The 2019 operating margin was reported at 23.6%, and the 2025 standalone margin is calculated at around 20%. The margin held up in a period of raw material cost increases, which supports the bull case.

Balance sheet strength and shareholder payouts

On a 2025 standalone basis, total liabilities were 2,300 million won against equity of 26,635 million won, a low leverage level. The shareholder meeting approved a cash dividend of 100 won per common share, a total of 502 million won and a 4.18% yield. Continued cash payouts are a financial strength.

06

Bear factors

Concentration on AED products

AED products accounted for 91.2% of revenue in 2019. The high-frequency stimulator and bone densitometer are secondary items, so diversification remains limited. Results depend heavily on pricing and procurement awards for one product group. Quarterly filings will show how far new products shift the revenue mix.

Reliance on public budgets and sales volatility

Procurement orders from the Public Procurement Service make up a large share of revenue. During the 2020 COVID-19 period, budget cuts reduced orders, and first-half sales fell 25.7% year on year. Budget cycles can cause sizable swings in quarterly results. Revenue growth in 2025 was modest relative to 2024.

A small market cap and limited trading

The market cap is about 8.4 billion won, and as a KONEX listing, trading volume is small. The external 52-week range of 1,500 to 2,450 won is wide.

07

Risk factors

Macro

Public procurement budgets depend on government fiscal conditions. During the 2020 COVID-19 period, reduced budgets from relevant ministries cut AED procurement volumes. Weaker investment by private medical institutions could affect private demand in the same direction.

Regulatory and certification

Overseas sales depend on country-specific certifications. The company built its export base through CE, PMDA and TGA certifications. Certification renewals or regulatory changes could shift export timing. Public procurement listing dates also influence when products can be sold.

Liquidity

As a KONEX-listed company with an 8.4 billion won market cap, Nanoomtech has limited tradable float because its largest shareholder holds 46.19%. Small trading volume can amplify price moves. The external 52-week range is 1,500 to 2,450 won.

08

Overall view

Nanoomtech is a medical device maker centered on automated external defibrillators, and its 2025 standalone operating margin was around 20%. Bullish factors include a business mix with both public and private demand, patent-backed pricing, low leverage and a maintained cash dividend.

Bearish factors include concentration in AED products, sales volatility from public budgets, and a small market cap with limited free float from its KONEX listing. Revenue rose modestly and operating profit rose more in 2025, but differing historical figures across data providers limit time-series analysis.

The exchange classifies the company under electrical equipment while its business is medical devices, which limits direct comparison with other sector peers. This summary is a qualitative overview provided for information purposes.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 8 more articles and sources
  1. comp.fnguide.com
  2. konex.or.kr
  3. news.nate.com
  4. m.news.nate.com
  5. digitaltoday.co.kr
  6. nanoomtech.co.kr
  7. komachine.com
  8. investing.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis